Siemens Healthcare Diagnostics Gmbh

Dade Behring Inc.

Zhu Teng

Tie Q Wei

Martin A Drinan

Manoj Sharma

Alan Robert Craig

William D Bedzyk

Carsten Schelp

Victor P Chu

Jie Li

Tatiana Mareeva

Chengrong X Wang

Qimu Liao

Roland Janzen

Izak Bahar

Jeffrey L Moore

Kelle M Garvey

Timothy J Gorzynski

Yuriy Smirnov

Gary Hickey

Ronald L Edwards

Yi Feng Zheng

Jason Snyder

Liping Geng

Steve P A Goss

Sandra A Lewisch

Nihmat Morjana

Allison Dominowski

Xiaodong Liu

Christine Moran

Ronald A Edwards

Heungyeung Yau

Richard C Wright

Bogdan Draghici

Lauren Seiple

Tatiana Lebedeva

Tie Quan Wei

Chengrong Wang

Antibodies that specifically bind naloxone or naltrexone are disclosed. Also disclosed are conjugates used in the production of the antibodies, as well as methods of producing the antibodies. Also disclosed are methods of using the antibodies in direct assays for naloxone or naltrexone. Further disclosed are methods of reducing naloxone or naltrexone interference in opiate assays using the antibodies.

Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof

The present invention relates to methods and compositions to remove or reduce biotin interference from certain assays.

Methods and compositions for removing biotin interference from assays using molecular traps

Kits containing a chemiluminescent detection system and microfluidics devices and methods for determining the concentration of biotin in a sample are disclosed. The kits, microfluidics devices, and methods utilize a sensitizer capable of generating singlet oxygen in its excited state and having avidin or an analog thereof directly or indirectly bound thereto, as well as a singlet oxygen-activatable chemiluminescent compound having biotin or an analog thereof directly or indirectly bound thereto.

Kits, microfluidics devices, and methods for performing biotin assays

The present disclosure includes compounds, kits, and assay procedures for use in determining the levels of certain types of drugs in samples that contain specific binding proteins for the drugs. The present disclosure includes analog compounds useful for displacing the drugs from their endogenous binding proteins, and kits including same, as well as methods that utilize these displacers as binding competitors in pharmaceutical assays.

Binding competitors for use in macrophilin-binding pharmaceutical assays and methods of use thereof

The present invention discloses compositions that comprise compounds relating to vitamin D. These compounds are useful for assays in the determination and distinguishing of certain 3-epimeric 25 hydroxyvitamin D and non-epimeric 25 hydroxyvitamin D. The compositions of the present invention may be used for example as immunogens used to develop antibodies to certain vitamin D compounds or conjugates used in assays for certain vitamin D compounds or used as a solid phase reagent in assays. The composition comprises a compound of one or more of the generic formula (R)-(L)-Z.

Compositions relating to vitamin D

Compounds include carbamate derivatives of vitamin D including vitamin Dand vitamin D. The compounds are useful in methods and kits for determining the presence and/or amount of vitamin D including vitamin D analogs and metabolites thereof in a sample suspected of containing the same.

Compositions and methods for detecting vitamin D

This invention relates to compositions, methods and kits for determining the presence and/or amount of vitamin D analytes, including vitamin D isomers, and metabolites thereof in a sample suspected of containing the same. Compounds include compounds of the Formula I, namely, (R)-(L)-Z wherein R, L, p and q are as defined herein. These compounds are capable of binding specifically to corresponding antibodies. Compounds and antibodies in accordance with the principles described herein can have therapeutic activity. These compounds may be administered in therapeutically effective amount, which is an amount to provide treatment of a particular disease state associated with vitamin D. Administration of the examples of compounds in accordance with the principles described herein can be by means of any of the accepted modes of administration for agents that serve similar utilities.

Antibodies are raised against compounds of Formula (I) where Z is an immunogenic carrier. These compounds are capable of binding specifically to corresponding antibodies. The antibodies are specific for epimers of vitamin D. Antibodies in accordance with the principles described herein may be employed to minimize or eliminate 3-epimer cross-reactivity in assays for non-epimeric forms of vitamin D analytes. Over-estimation of total non-epimeric vitamin D analyte caused by the cross-reactivity of 3-epimer vitamin D with an antibody for vitamin D analyte can be substantially avoided employing, as blocking agents, antibodies prepared against immunogens that are a compound of the Formula (I) wherein Z is an immunogenic carrier. 

Binding partners specific for vitamin D epimers

Methods include determining an amount of an epimeric vitamin D analyte in a sample suspected of containing the epimeric vitamin D analyte. A combination is provided in an assay medium that includes the sample and a vitamin D epimer antibody that is specific for the epimeric vitamin D analyte. The assay medium is incubated under conditions for binding of the vitamin D epimer antibody to the epimeric vitamin D analyte to form an epimeric vitamin D antibody-bound complex. The amount of the epimeric vitamin D antibody-bound complex is determined and related to the amount of epimeric vitamin D analyte in the sample.

Assays for vitamin D epimers

Methods include determining an amount of vitamin D analyte in a sample suspected of containing the vitamin D analyte. A combination is provided in an assay medium that includes the sample, a vitamin D epimer antibody that is specific for epimers of the vitamin D analyte wherein the vitamin D epimer antibody does not bind to any detectable degree to the vitamin D analyte, and a vitamin D antibody that is specific for the vitamin D analyte, and. The assay medium is incubated under conditions for binding of the vitamin D epimer antibody to the epimers of the vitamin D analyte and for binding of the vitamin D antibody to the vitamin D analyte to form a vitamin D antibody-bound complex. The amount of vitamin D antibody-bound complex is determined and related to the amount of vitamin D analyte in the sample.

Binding partners specific for vitamin D epimers in vitamin D assays

Methods of detecting Cortisol in samples suspected of containing Cortisol are disclosed that utilize conjugates of 11-a-cortisol linked at the 3-position to an assay molecule. In addition, compounds are disclosed that have the formula: (structure) wherein L is a linking group and X is as further defined herein. 

Compositions and methods for detecting cortisol

Methods and reagents are disclosed for conducting assays. Embodiments of the present methods and reagents are concerned with a solid support such as, for example, a particle. The support includes a chemiluminescent composition that includes a metal chelate. The present inventors observed that, when such support such as, e.g., particles, were employed in assays for the determination of an analyte, stability of signal output by the chemiluminescent composition associated with the particle was unacceptably reduced as compared to particles including other chemiluminescent compositions. In accordance with embodiments of the present invention, the stability of signal output from such particles is enhanced by including in a medium that contains the particles a sufficient amount of one or more stabilizing agents, which may be a chelating agent and/or a metal chelate such as, for example, the metal chelate that is associated with the particle.

Stabilization of signal generation in particles used in assays

The present invention relates to immobilized procainamide analogs, as well as to a method of making immobilized procainamide analogs. These immobilized analogs are prepared by activating the carboxyl group on a substituted p-benzoic acid derivative toward nucleophilic attack; reacting the activated benzoic acid derivative with a polyamine to produce the benzoic acid derivative of Formula 3: and binding the benzoic acid derivative of Formula 3 to a latex polymer having functional groups that react with aliphatic amino groups. A method of conducting an immunoassay using the immobilized procainamide analog Formula 3 is described, comprising the steps of preparing a solution comprising said immobilized procainamide analog; adding a sample suspected of containing procainamide to said solution; adding an anti-procainamide antibody to said solution and observing the rate of increase in solution turbidity following antibody addition.

Synthesis and application of procainamide analogs for use in an immunoassay

Compositions suitable for use as signal generation components of an immunoassay, and methods for their use. According to one aspect of the invention, the composition includes a carrier having a coating of an aminodextran and a metal chelate incorporated therein. The metal chelate is present in the amount of at least 0.065 &#x3bc;Mole per gram of carrier, and the aminodextran coating density averaging at least about 45 &#x3bc;g per milligram of carrier. In another aspect of the invention, carrier is dyed with a complex having the formula:M(L1)(L2), wherein R is one or more substituents, each substituent comprising an electron donating group; n=2-10; x=1-2; and y=2-4.

Growing community of inventors

Garnet Valley, PA, United States of America

Zhu Teng